Targeted antiestrogens for the prevention of breast cancer

David J. Bentrem*, V. Craig Jordan

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


This commentary explores the recent experience with and the basis for the use of selective estrogen receptor modulators (SERMs) to prevent breast cancer. Chcmoprevention has been a goal for many years. As newer agents arc unveiled, they will continue to be tested against tamoxifen, the current standard for the treatment and prevention of breast cancer. Raloxifene holds the promise of treating osteoporosis with the beneficial side effect of breast cancer prevention. The Study of Tamoxifen and Raloxifene (STAR) trial and prior prevention studies will be discussed in an attempt understand the bridge from the laboratory to the clinic.

Original languageEnglish (US)
Pages (from-to)401-407
Number of pages7
JournalOncology Research
Issue number9
StatePublished - 1999


  • Antiestrogens
  • Breast cancer
  • Raloxifene
  • Tamoxifen

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Targeted antiestrogens for the prevention of breast cancer'. Together they form a unique fingerprint.

Cite this